Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update

K. R. Crews, A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, T. E. Klein, K. E. Caudle, C. E. Haidar, D. D. Shen, J. T. Callaghan, S. Sadhasivam, C. A. Prows, E. D. Kharasch, T. C. Skaar

Research output: Contribution to journalArticle

342 Scopus citations

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

Original languageEnglish (US)
Pages (from-to)376-382
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume95
Issue number4
DOIs
StatePublished - Apr 2014

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update'. Together they form a unique fingerprint.

  • Cite this

    Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., Prows, C. A., Kharasch, E. D., & Skaar, T. C. (2014). Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update. Clinical Pharmacology and Therapeutics, 95(4), 376-382. https://doi.org/10.1038/clpt.2013.254